

# Elecsys Prolactin II

REF			SYSTEM
09755764190	09755764500	100	cobas e 402 cobas e 801

## English

### System information

Short name	ACN (application code number)
PRL 2	10111

### Intended use

Immunoassay for the in vitro quantitative determination of prolactin in human serum and plasma.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on **cobas e** immunoassay analyzers.

### Summary

Prolactin measurements, performed with this assay, in human serum and plasma, are used in the diagnosis of hyperprolactinemia, associated with endocrine disorders and infertility.

Prolactin is synthesized in the anterior pituitary and is secreted in episodes by lactotroph cells. Prolactin appears in serum in three different forms: the monomeric form ("little" prolactin, 23 kDa), the dimeric form ("big" prolactin, 48 to 56 kDa) and the polymeric form ("big-big" prolactin, > 100 kDa).<sup>1</sup> Occasionally immunoglobulin G autoantibodies against prolactin can bind to prolactin, forming a macromolecular complex called macroprolactin. The presence of macroprolactin elevates the total serum concentration of prolactin.<sup>2,3</sup>

Prolactin secretion is predominantly controlled through suppression by dopamine. Factors inducing prolactin synthesis and secretion include estrogen, thyrotropin-releasing hormone, epidermal growth factor, and dopamine receptor antagonists. High concentrations of prolactin reduce luteinising hormone (LH) and follicle stimulating hormone (FSH) by inhibiting the secretion of gonadotropin releasing hormone (GnRH).<sup>1</sup>

Hyperprolactinemia (in men and women) is a cause of fertility disorders. Oligomenorrhea, amenorrhea and infertility in hyperprolactinemic women (premenopausal: > 30 ng/mL, postmenopausal: > 20 ng/mL), and impotence and oligospermia in hyperprolactinemic men (> 20 ng/mL), result from prolactin suppression of GnRH secretion.<sup>1</sup>

During pregnancy, the concentration of prolactin rises under the influence of sex hormones (predominantly estradiol).<sup>1,4</sup> In women, prolactin stimulates and sustains postpartum lactation; low postpartum levels of prolactin can be a cause of lactation failure after childbirth.<sup>1,5,6</sup>

Nonpuerperal hyperprolactinemia is one of the most common endocrine disorders and may be caused by lactotroph adenomas (prolactinomas, approximately 40 % of all pituitary tumors), by pharmacological or pathological interruption of hypothalamic-pituitary dopaminergic pathways or it can sometimes be idiopathic.<sup>4</sup>

Emotional stress, physical exercise and a protein-rich diet can all stimulate prolactin secretion.<sup>1,4,7</sup> Metabolic disorders related to gluco-insulinemic and lipid profile are commonly reported in patients with prolactin excess.<sup>8,9</sup> Pharmacological modulation of the hypothalamic dopamine system and/or the pituitary dopamine receptors can affect prolactin levels.<sup>10,11,12,13,14,15</sup>

Low circulating prolactin levels can be the consequence of: abnormal lactotroph cell development (genetic causes), destruction of pituitary tissue (Sheehan syndrome, inflammation or autoimmune lactotroph damage, tumor or surgery, tuberculosis infection), pseudohypoparathyroidism, idiopathic prolactin deficiency, medications (e.g. dopamine agonist).<sup>15</sup> Isolated prolactin deficiency is rare and mainly manifests clinically in women after childbirth with puerperal alactogenesis.<sup>5,16</sup> The incidence of severe prolactin deficiency in patients with acquired prolactin deficiency increases alongside an increase in the number of other anterior pituitary hormone defects.<sup>15</sup>

The Elecsys Prolactin II assay uses two monoclonal antibodies specifically directed against human prolactin.<sup>17</sup> Both antibodies show a low reactivity with most forms of macroprolactin.

### Test principle

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: 6 µL of sample and a biotinylated monoclonal prolactin-specific antibody form a first complex.
- 2nd incubation: After addition of a monoclonal prolactin-specific antibody labeled with a ruthenium complex<sup>a)</sup> and streptavidin-coated microparticles, a sandwich complex is formed and becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell II M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the **cobas** link.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)<sub>3</sub><sup>2+</sup>)

### Reagents - working solutions

The **cobas e** pack is labeled as PRL 2.

- M Streptavidin-coated microparticles, 1 bottle, 6.4 mL:  
Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-prolactin-Ab~biotin, 1 bottle, 9.0 mL:  
Biotinylated monoclonal anti-prolactin antibody (mouse) 0.7 mg/mL;  
phosphate buffer 50 mmol/L, pH 7.0; preservative.
- R2 Anti-prolactin-Ab~Ru(bpy)<sub>3</sub><sup>2+</sup>, 1 bottle, 9.0 mL:  
Monoclonal anti-prolactin antibody (mouse) labeled with ruthenium complex 0.35 mg/L; phosphate buffer 50 mmol/L, pH 7.0;  
preservative.

### Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:



### Warning

H317 May cause an allergic skin reaction.

### Prevention:

P261 Avoid breathing mist or vapours.

P272 Contaminated work clothing should not be allowed out of the workplace.

P280 Wear protective gloves.

### Response:

P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

### Disposal:

# Elecsys Prolactin II

P501 Dispose of contents/container to an approved waste disposal plant.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

## Reagent handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is available via the **cobas** link.

## Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the **cobas e** pack **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
on the analyzers	16 weeks

## Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, K<sub>2</sub>-EDTA and K<sub>3</sub>-EDTA plasma.

Criterion: Slope 0.9-1.1 + intercept within  $\pm 10$   $\mu$ U/mL + coefficient of correlation  $\geq 0.95$ .

Stable for 5 days at 20-25 °C, 14 days at 2-8 °C, 6 months at -20 °C ( $\pm 5$  °C). Freeze only once.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use heat-inactivated samples.

Do not use samples and controls stabilized with azide.

Ensure the samples and calibrators are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples and calibrators on the analyzers should be analyzed/measured within 2 hours.

## Materials provided

See "Reagents – working solutions" section for reagents.

## Materials required (but not provided)

- [REF] 03277356190, Prolactin II CalSet, for 4 x 1.0 mL
- [REF] 11731416190, PreciControl Universal, for 4 x 3.0 mL
- [REF] 07299001190, Diluent Universal, 36 mL sample diluent
- General laboratory equipment
- **cobas e** analyzer

Additional materials for **cobas e** 402 and **cobas e** 801 analyzers:

- [REF] 06908799190, ProCell II M, 2 x 2 L system solution
- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF] 07485409001, Reservoir Cup, 8 cups to supply ProCell II M and CleanCell M
- [REF] 06908853190, PreClean II M, 2 x 2 L wash solution
- [REF] 05694302001, Assay Tip/Assay Cup tray, 6 magazines x 6 magazine stacks x 105 assay tips and 105 assay cups, 3 wasteliners

- [REF] 07485425001, Liquid Flow Cleaning Cup, 2 adaptor cups to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning Detection Unit
- [REF] 07485433001, PreWash Liquid Flow Cleaning Cup, 1 adaptor cup to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning PreWash Unit
- [REF] 11298500316, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

## Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use.

Place the cooled (stored at 2-8 °C) **cobas e** pack on the reagent manager. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the **cobas e** pack.

## Calibration

Traceability: This method has been standardized against the 3rd IRP WHO Reference Standard 84/500.

The predefined master curve is adapted to the analyzer using the relevant CalSet.

*Calibration frequency:* Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the **cobas e** pack was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 12 weeks when using the same reagent lot
- after 28 days when using the same **cobas e** pack on the analyzer
- as required: e.g. quality control findings outside the defined limits

## Quality control

Use PreciControl Universal or other suitable controls for routine quality control procedures.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per **cobas e** pack, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

## Calculation

The analyzer automatically calculates the analyte concentration of each sample (either in  $\mu$ U/mL, ng/mL or in mIU/L).

$$\begin{aligned} \text{Conversion factors:} \quad & \mu\text{U/mL (mIU/L)} \times 0.047 = \text{ng/mL} \\ & \text{ng/mL} \times 21.2 = \mu\text{U/mL (mIU/L)} \end{aligned}$$

## Limitations - interference

The effect of the following endogenous substances and pharmaceutical compounds on assay performance was tested. Interferences were tested up to the listed concentrations and no impact on results was observed.

### Endogenous substances

Compound	Concentration tested
Bilirubin	$\leq 513$ $\mu$ mol/L or $\leq 30$ mg/dL
Hemoglobin	$\leq 0.932$ mmol/L or $\leq 1500$ mg/dL
Intralipid	$\leq 1500$ mg/dL
Biotin	$\leq 164$ nmol/L or $\leq 40$ ng/mL
Rheumatoid factors	$\leq 1100$ IU/mL

# Elecsys Prolactin II

Criterion: For concentrations of 2-50  $\mu\text{IU/mL}$  the deviation is  $\leq \pm 10 \mu\text{IU/mL}$ . For concentrations > 50-100  $\mu\text{IU/mL}$  the deviation is  $\pm 20 \%$ . For concentrations > 100  $\mu\text{IU/mL}$  the deviation is  $\pm 15 \%$ .

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

There is no high-dose hook effect at prolactin concentrations up to 270000  $\mu\text{IU/mL}$  (12690 ng/mL).

## Pharmaceutical substances

In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

When determining prolactin it should be remembered that the measured concentration is dependent upon when the blood sample was taken, since the secretion of prolactin occurs in episodes and is also subject to a 24-hour cycle.<sup>18,19</sup>

The release of prolactin is inhibited by dopamine, L-dopa and ergotamine derivatives.

A number of publications report the presence of macroprolactin in the serum of female patients with various endocrinological diseases or during pregnancy. Differing degrees of detection of the serum macroprolactins relative to monomeric prolactin (22-23 kDa) by various immunoassays have also been described. This could lead to a false diagnosis of hyperprolactinemia depending on the immunoassay used.<sup>17</sup>

In case of implausible high prolactin values a precipitation by polyethylene glycol (PEG) is recommended in order to estimate the amount of the biological active monomeric prolactin.

See section "Sample pretreatment by polyethylene glycol (PEG) precipitation" for further details.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

## Limits and ranges

### Measuring range

2-10000  $\mu\text{IU/mL}$  or 0.094-470 ng/mL (defined by the lower detection limit and the maximum of the master curve). Values below the lower detection limit are reported as < 2  $\mu\text{IU/mL}$  or < 0.094 ng/mL. Values above the measuring range are reported as > 10000  $\mu\text{IU/mL}$  or > 470 ng/mL (or up to 100000  $\mu\text{IU/mL}$  or 4700 ng/mL for 10-fold diluted samples).

### Lower limits of measurement

Limit of Blank, Limit of Detection and Limit of Quantitation

Limit of Blank = 1  $\mu\text{IU/mL}$  (0.047 ng/mL)

Limit of Detection = 2  $\mu\text{IU/mL}$  (0.094 ng/mL)

Limit of Quantitation = 20  $\mu\text{IU/mL}$  (0.940 ng/mL)

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95<sup>th</sup> percentile value from  $n \geq 60$  measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with an intermediate precision CV of  $\leq 20 \%$ .

## Dilution

Samples with prolactin concentrations above the measuring range can be diluted with Diluent Universal. The recommended dilution is 1:10 (either automatically by the analyzers or manually). The concentration of the diluted sample must be  $\geq 50 \mu\text{IU/mL}$  or  $\geq 2.40 \text{ ng/mL}$ .

After manual dilution, multiply the result by the dilution factor.

After dilution by the analyzers, the software automatically takes the dilution into account when calculating the sample concentration.

## Expected values

A study with the Elecsys Prolactin II assay was performed using samples from 300 apparently healthy blood donors. The following results were obtained:

	N	Percentiles			
		50 <sup>th</sup>	2.5-97.5 <sup>th</sup>	50 <sup>th</sup>	2.5-97.5 <sup>th</sup>
		$\mu\text{IU/mL}$		ng/mL	
Men	102	155	86-324	7.30	4.04-15.2
Women (not-pregnant)	198	225	102-496	10.6	4.79-23.3

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Moreover, it should be remembered that the measured concentration is dependent upon when the blood sample was taken, since the secretion of prolactin occurs in episodes and is also subject to a 24-hour cycle.<sup>18,19</sup>

## Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

## Precision

Precision was determined using Elecsys reagents, pooled human sera and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days ( $n = 84$ ). The following results were obtained:

cobas e 402 and cobas e 801 analyzers								
Sample	Mean		Repeatability			Intermediate precision		
			SD		CV	SD		CV
	$\mu\text{IU/mL}$	ng/mL	$\mu\text{IU/mL}$	ng/mL	%	$\mu\text{IU/mL}$	ng/mL	%
HS <sup>b)</sup> 1	10.5	0.494	0.269	0.013	2.6	0.313	0.015	3.0
HS 2	73.6	3.46	2.26	0.106	3.1	2.81	0.132	3.8
HS 3	598	28.1	10.6	0.498	1.8	15.9	0.747	2.7
HS 4	2017	94.8	47.4	2.23	2.4	58.6	2.75	2.9
HS 5	5612	264	115	5.41	2.1	162	7.61	2.9
HS 6	8343	392	178	8.37	2.1	295	13.9	3.5
PC <sup>c)</sup> Universal1	253	11.9	5.13	0.241	2.0	6.62	0.311	2.6
PC Universal2	874	41.1	17.5	0.823	2.0	38.0	1.79	4.4

b) HS = human serum

c) PC = PreciControl

## Method comparison

a) A comparison of the Elecsys Prolactin II assay, [REF] 07027737190 (cobas e 801 analyzer; y) with the Elecsys Prolactin II assay, [REF] 03203093190 (cobas e 601 analyzer; x) gave the following correlations ( $\mu\text{IU/mL}$ ):

Number of samples measured: 132

Passing/Bablok<sup>20</sup> Linear regression

$y = 1.02x - 0.238$

$y = 1.01x + 8.64$

$\tau = 0.985$

$r = 0.999$

The sample concentrations were between 2.63 and 9693  $\mu\text{IU/mL}$ .

b) A comparison of the Elecsys Prolactin II assay, [REF] 07027737190 (cobas e 402 analyzer; y) with the Elecsys Prolactin II assay, [REF] 07027737190 (cobas e 801 analyzer; x) gave the following correlations ( $\mu\text{IU/mL}$ ):

Number of samples measured: 207

# Elecsys Prolactin II

Passing/Bablok<sup>20</sup>

Linear regression

$$y = 0.973x - 0.409$$

$$y = 0.968x + 2.14$$

$$\tau = 0.990$$

$$r = 1.00$$

The sample concentrations were between 4.13 and 9857  $\mu\text{U/mL}$ .

## Analytical specificity

The monoclonal antibodies used are highly specific against prolactin. No cross reaction with hGH, hCG, hPL, TSH, FSH and LH has been observed.

## Sample pretreatment by polyethylene glycol (PEG) precipitation

### Test principle

Macroprolactin and oligomers can be precipitated by using a 25 % aqueous PEG solution (ratio 1+1). After centrifugation, the supernatant containing monomeric prolactin is used in the Elecsys Prolactin II assay in the same way as a native sample. The dilution effect which occurs during sample pretreatment and the coprecipitation of monomeric prolactin must be taken into consideration.

### Reagents (not provided)

- Polyethylene glycol 6000 (e.g. available from Serva, Cat. No. 33137)
- Sigma PEG 6000 (e.g. available from Sigma-Aldrich CAS 25322-68-3)
- Distilled or deionized water

### Precautions and warnings

See instructions provided by the manufacturer of the polyethylene glycol 6000.

### Reagent handling

To prepare a 25 % PEG solution, dissolve 25 g polyethylene glycol 6000 in approximately 60 mL of distilled or deionized water at 18-25 °C (magnetic stirrer, 15 minutes) and fill up to 100 mL.

### Storage and stability

Store the original substance according to the instructions of the manufacturer.

Store the 25 % PEG solution at 20-25 °C.

Stability of the solution: 7 days.

### Materials required (but not provided)

- Magnetic stirrer
- Rotating shaker (vortex)
- Centrifuge (1500 g to 10000 g)

### Assay

Sample pretreatment (18-25 °C):

- Mix appropriate volume of sample (at least 180  $\mu\text{L}$ ) with PEG solution at a ratio of 1+1
- Mix well for approximately 10 seconds in a rotating shaker (vortex)
- Centrifuge for 5 minutes between 1500 g and 10000 g (within 1-30 minutes)

Analyze the supernatant in the same way as the native samples.

### Calculation

Approximately 14 % (range: 0-40 %) of monomeric prolactin is coprecipitated by PEG.<sup>21</sup> The dilution effect which occurs during PEG treatment and the coprecipitation of monomeric prolactin must be taken into consideration when calculating the results.

After precipitation by PEG each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

### References

- 1 Holmes DT, Bertholf RL, Winter WE. Pituitary Function and Pathophysiology. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, editors. Tietz Textbook of Laboratory Medicine, Saunders Elsevier, Philadelphia, 7th edition, 2023, chapter 55, p. 767-804.e10.
- 2 Fahie-Wilson MN, Brunnsden P, Surrey J, et al. Macroprolactin and the Roche Elecsys Prolactin assay: characteristics of the reaction and detection by precipitation with polyethylene glycol. Clin Chem 2000;46:1993-1995.

- 3 Fahie-Wilson MN, Soule SG. Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann Clin Biochem 1997;34:252-258.
- 4 Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96(2):273-288.
- 5 Iwama S, Welt CK, Romero CJ, et al. Isolated prolactin deficiency associated with serum autoantibodies against prolactin-secreting cells. J Clin Endocrinol Metab. 2013 Oct;98(10):3920-5.
- 6 Berens PD, Villanueva M, Nader S, et al. Isolated Prolactin Deficiency: A Possible Culprit in Lactation Failure. AACCE Clinical Case Reports. 2018;4(6):e509-e12.
- 7 Whyte MB, Pramodh S, Srikugan L, et al. Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary 2015;18:319-325.
- 8 Pirchio R, Graziadio C, Colao A, et al. Metabolic effects of prolactin. Front Endocrinol (Lausanne). 2022 Sep 27;13:1015520.
- 9 Ben Jonathan N, Hugo ER, Brandebourg TD, et al. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006;17(3):110-116.
- 10 Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem. 2010 Jul;47(Pt 4):292-300.
- 11 Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol. 2007 Sep;21(7):768-73.
- 12 Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol. 2008 Mar;22(2 Suppl):98-103.
- 13 Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005 Aug;80(8):1050-7.
- 14 Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics--a review. Hum Psychopharmacol. 2010 Jun-Jul;25(4):281-97.
- 15 Bernard V, Young J, Binart N. Prolactin - a pleiotropic factor in health and disease. Nat Rev Endocrinol. 2019 Jun;15(6):356-365.
- 16 Kauppila A. Isolated prolactin deficiency. Curr Ther Endocrinol Metab. 1997;6:31-3.
- 17 Fahie-Wilson M, Smith TP. Determination of prolactin: The macroprolactin problem. Best Pract Res Clin Endocrinol Metab 2013;27:725-742.
- 18 Roelfsema F, Pijl H, Keenan DM, et al. Prolactin secretion in healthy adults is determined by gender, age and body mass index. PLoS ONE 2012;7(2):e31305.
- 19 Aitkenhead H, Heales SJ. Establishment of paediatric age-related reference intervals for serum prolactin to aid in the diagnosis of neurometabolic conditions affecting dopamine metabolism. Ann Clin Biochem 2013;50:156-158.
- 20 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.
- 21 Sapin R, Gasser F, Grucker D. Free prolactin determinations in hyperprolactinemic men with suspicion of macroprolactinemia. Clin Chim Acta 2002;316:33-41.

For further information, please refer to the appropriate user guide or operator's manual for the analyzer concerned, the respective application sheets and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

# Elecsys Prolactin II



## Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see [navifyportal.roche.com](http://navifyportal.roche.com) for definition of symbols used):

	Contents of kit
	Analyzers/Instruments on which reagents can be used
	Reagent
	Calibrator
	Volume for reconstitution
	Global Trade Item Number

Rx only                      For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

---

COBAS, NAVIFY, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2024, Roche Diagnostics



 Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim  
[www.roche.com](http://www.roche.com)  
 +800 5505 6606

